Baillie Gifford & Co. Makes New Investment in Billiontoone, Inc. $BLLN

Key Points

• Baillie Gifford & Co. acquired a new position of 1,268,163 shares of Billiontoone (NASDAQ: BLLN), valued at about $103,786,000 and representing roughly 2.77% of the company.
• Billiontoone beat quarterly expectations, reporting $0.11 EPS vs. $0.04 consensus and $96.05M revenue vs. $85.85M consensus, with revenue up 113% year‑over‑year.
• Analyst sentiment is mixed: the consensus is a "Moderate Buy" with an average target of $126.71, but several firms have cut targets and the breakdown is 6 buys, 3 holds, 1 sell.

Baillie Gifford & Co. acquired a new position in Billiontoone, Inc. (NASDAQ:BLLN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,268,163 shares of the company's stock, valued at approximately $103,786,000. Baillie Gifford & Co. owned approximately 2.77% of Billiontoone as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Massachusetts Financial Services Co. MA acquired a new position in Billiontoone in the fourth quarter worth $13,373,000. FNY Investment Advisers LLC acquired a new position in shares of Billiontoone during the fourth quarter valued at $497,000. Finally, Green Alpha Advisors LLC acquired a new position in shares of Billiontoone during the fourth quarter valued at $436,000.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Weiss Ratings assumed coverage on Billiontoone in a research note on Tuesday, February 3rd. They set a "sell (d)" rating on the stock. Wells Fargo & Company cut their price target on Billiontoone from $110.00 to $90.00 and set an "equal weight" rating on the stock in a research note on Thursday, March 5th. Guggenheim cut their price target on Billiontoone from $120.00 to $100.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. BTIG Research cut their price target on Billiontoone from $160.00 to $140.00 and set a "buy" rating on the stock in a research note on Thursday, March 5th. Finally, Wall Street Zen raised Billiontoone from a "hold" rating to a "buy" rating in a research note on Saturday, March 7th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $126.71.

Billiontoone Trading Down 3.0%

NASDAQ BLLN opened at $78.70 on Tuesday. The firm has a 50-day moving average of $79.24. The company has a market capitalization of $3.62 billion and a P/E ratio of 374.76. The company has a quick ratio of 11.32, a current ratio of 11.69 and a debt-to-equity ratio of 0.12. Billiontoone, Inc. has a 12 month low of $61.96 and a 12 month high of $138.70.

Billiontoone (NASDAQ:BLLN - Get Free Report) last released its quarterly earnings data on Wednesday, March 4th. The company reported $0.11 EPS for the quarter, beating analysts' consensus estimates of $0.04 by $0.07. The company had revenue of $96.05 million during the quarter, compared to the consensus estimate of $85.85 million. The company's revenue was up 113.0% compared to the same quarter last year.

About Billiontoone

BillionToOne NASDAQ: BLLN is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.